Regeneron's Great Science Led To An Important Drug. But Will It Flop Commercially? [Forbes]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Forbes
Regeneron's Great Science Led To An Important Drug. But Will It Flop Commercially? Homozygous familial hypercholesterolemia (HoFH) is an insidious disease. People so afflicted are born without low density lipoprotein (LDL) receptors – the receptors that are responsible for clearing this atherosclerosis causing protein through the liver. People with HoFH have cholesterol levels five times that of a normal person and, as a result, are prone to heart attacks and strokes at an early age. In fact, according to the FH Foundation, HoFH causes narrowing and blocking of blood vessels Leonard S. Schleifer, president and chief executive officer of Regeneron Pharmaceuticals Inc. Photographer: Eric Thayer/Bloomberg © 2016 Bloomberg Finance LP HoFH must be treated aggressively. LDL apheresis, which involves cleansing a patient’s blood of LDL-cholesterol (LDL-c), is performed at least every other week. In addition, drugs that reduce cholesterol absorption like ezetimibe or that prevent the body from
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) [Yahoo! Finance]Yahoo! Finance
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)GlobeNewswire
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution [Yahoo! Finance]Yahoo! Finance
- Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)GlobeNewswire
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- REGN's page on the SEC website